Bio Green Med Solution Inc (BGMS)

$0.94 +0.02 (2.17%)
Market Cap 4.46M
Revenue (ttm) 40,000.00
Net Income (ttm) -11.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28,025.00%
Debt to Equity Ratio 0.00
Volume 33,900
Avg Vol 91,978
Day's Range N/A - N/A
Shares Out 4.90M
Stochastic %K 82%
Beta -0.45
Analysts Hold
Price Target N/A

Company Profile

Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. It also researches and develops pharmaceuticals. The company was formerly known as Cyclacel Pharmaceuticals, Inc. and changed its name to Bio Green Med Solution, Inc. in September 2022. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

Industry: Biotechnology
Sector: Healthcare
Phone: 60 9 08517 7330
Address:
Level 10, Tower 11 Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia
FoxyDreams
FoxyDreams Mar. 16 at 8:54 PM
’:@SqueezeSharkie is on a different level, ahead of 90% of traders on this platform. If you’re not following yet, you’re missing out. Takes 2 seconds and it’s free💎 $DGXX $RVSN $BGMS $SLS >>> on watch!!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 16 at 8:03 PM
$BGMS RSI: 40.58, MACD: -0.0637 Vol: 0.05, MA20: 0.98, MA50: 1.14 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TradeScouts
TradeScouts Mar. 13 at 6:01 AM
$BGMS The company completed the acquisition of FITTERS Sdn. Bhd., a Malaysia-based fire protection specialist.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 24 at 6:49 PM
$BGMS RSI: 45.99, MACD: -0.0886 Vol: 0.11, MA20: 1.06, MA50: 1.27 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
bahjatbern
bahjatbern Feb. 23 at 12:38 PM
$BGMS old scam ticker , old name CYCC,, should be delisted soon
0 · Reply
SqueezeMagnet33
SqueezeMagnet33 Feb. 21 at 11:01 PM
$MSS Volume increased on Friday !! Watch this one . Shorts about to lose control . May go crazy . ✅ $BGMS Unknown .. ppl will discover it soon . 👀 $RMSG Unsual vol $MGRX got Crazy
1 · Reply
SqueezeMagnet33
SqueezeMagnet33 Feb. 19 at 9:40 PM
$BGMS Seems thin .. Likely to squeeze soon ✅
1 · Reply
Highprofits009
Highprofits009 Feb. 18 at 11:22 PM
$BGMS
0 · Reply
TigerPicks6
TigerPicks6 Feb. 18 at 10:20 PM
$BGMS Low float Being Loaded . watch and Wait . Gonna go .✌️ $BOXL did it ! Thx Zalmy $TMDE and $YIBO Held and banked . great day ! 🩲 My lucky undies probly ! :)
0 · Reply
SqueezeMagnet33
SqueezeMagnet33 Feb. 18 at 12:30 PM
$BGMS being accumulated ... Watch this one .
0 · Reply
Latest News on BGMS
Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update

Nov 13, 2025, 4:40 PM EST - 4 months ago

Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update

BGMS

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Aug 13, 2025, 4:05 PM EDT - 7 months ago

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

Aug 4, 2025, 6:50 PM EDT - 8 months ago

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

Jul 15, 2025, 12:17 PM EDT - 8 months ago

Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

Jul 7, 2025, 6:00 AM EDT - 9 months ago

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

Jul 7, 2025, 6:00 AM EDT - 9 months ago

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

Cyclacel Pharmaceuticals Announces Stock Split

Jul 2, 2025, 9:00 AM EDT - 9 months ago

Cyclacel Pharmaceuticals Announces Stock Split

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

Jun 20, 2025, 4:30 PM EDT - 9 months ago

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Jun 3, 2025, 4:15 PM EDT - 10 months ago

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 15, 2025, 12:50 AM EDT - 11 months ago

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

May 7, 2025, 9:00 AM EDT - 11 months ago

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

May 6, 2025, 6:00 AM EDT - 11 months ago

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Mar 24, 2025, 7:30 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Feb 27, 2025, 1:38 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Jan 3, 2025, 9:01 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Dec 5, 2024, 4:05 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 14, 2024, 4:15 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 13, 2024, 12:22 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Nov 12, 2024, 4:45 PM EST - 1 year ago

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Oct 24, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 23, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 9, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Sep 25, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Sep 3, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Aug 7, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Jun 26, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

May 8, 2024, 9:15 AM EDT - 2 years ago

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

May 2, 2024, 4:30 PM EDT - 2 years ago

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 30, 2024, 7:00 AM EDT - 2 years ago

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Apr 1, 2024, 9:15 AM EDT - 2 years ago

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:05 PM EDT - 2 years ago

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Mar 13, 2024, 4:05 PM EDT - 2 years ago

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 7, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Mar 6, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Feb 20, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Jan 30, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jan 8, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Jan 2, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Dec 22, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Dec 18, 2023, 9:00 AM EST - 2 years ago

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Cyclacel Pharmaceuticals Announces Reverse Stock Split

Dec 12, 2023, 4:05 PM EST - 2 years ago

Cyclacel Pharmaceuticals Announces Reverse Stock Split

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Nov 30, 2023, 9:15 AM EST - 2 years ago

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

Nov 28, 2023, 5:15 PM EST - 2 years ago

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

Nov 7, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

Aug 3, 2023, 9:15 AM EDT - 2 years ago

Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

May 11, 2023, 4:05 PM EDT - 3 years ago

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results

May 4, 2023, 9:15 AM EDT - 3 years ago

Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results

FoxyDreams
FoxyDreams Mar. 16 at 8:54 PM
’:@SqueezeSharkie is on a different level, ahead of 90% of traders on this platform. If you’re not following yet, you’re missing out. Takes 2 seconds and it’s free💎 $DGXX $RVSN $BGMS $SLS >>> on watch!!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 16 at 8:03 PM
$BGMS RSI: 40.58, MACD: -0.0637 Vol: 0.05, MA20: 0.98, MA50: 1.14 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TradeScouts
TradeScouts Mar. 13 at 6:01 AM
$BGMS The company completed the acquisition of FITTERS Sdn. Bhd., a Malaysia-based fire protection specialist.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 24 at 6:49 PM
$BGMS RSI: 45.99, MACD: -0.0886 Vol: 0.11, MA20: 1.06, MA50: 1.27 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
bahjatbern
bahjatbern Feb. 23 at 12:38 PM
$BGMS old scam ticker , old name CYCC,, should be delisted soon
0 · Reply
SqueezeMagnet33
SqueezeMagnet33 Feb. 21 at 11:01 PM
$MSS Volume increased on Friday !! Watch this one . Shorts about to lose control . May go crazy . ✅ $BGMS Unknown .. ppl will discover it soon . 👀 $RMSG Unsual vol $MGRX got Crazy
1 · Reply
SqueezeMagnet33
SqueezeMagnet33 Feb. 19 at 9:40 PM
$BGMS Seems thin .. Likely to squeeze soon ✅
1 · Reply
Highprofits009
Highprofits009 Feb. 18 at 11:22 PM
$BGMS
0 · Reply
TigerPicks6
TigerPicks6 Feb. 18 at 10:20 PM
$BGMS Low float Being Loaded . watch and Wait . Gonna go .✌️ $BOXL did it ! Thx Zalmy $TMDE and $YIBO Held and banked . great day ! 🩲 My lucky undies probly ! :)
0 · Reply
SqueezeMagnet33
SqueezeMagnet33 Feb. 18 at 12:30 PM
$BGMS being accumulated ... Watch this one .
0 · Reply
FadeTracker
FadeTracker Feb. 18 at 9:32 AM
$BGMS Thin float and news-driven volatility dominate trading behavior.
0 · Reply
gammaeddy
gammaeddy Feb. 17 at 8:34 AM
$BGMS Obscure micro-cap; minimal coverage
0 · Reply
StockScanners
StockScanners Feb. 10 at 4:09 AM
$BGMS reached 1.18
0 · Reply
StockScanners
StockScanners Feb. 8 at 4:10 AM
$BGMS keep watch if this holds above 1
0 · Reply
fromtheothersid3
fromtheothersid3 Feb. 6 at 7:54 PM
$BGMS Looks good to me ☺️
0 · Reply
fromtheothersid3
fromtheothersid3 Feb. 6 at 7:43 PM
$BGMS lets do another Monster Run... I be happy with 8$ 😆☺️ But WE do have an unreal tight free float... Never know, i got my ticket ❤️
0 · Reply
BearishAlgo
BearishAlgo Feb. 6 at 7:13 PM
$BGMS covered/closed here at 1.12
0 · Reply
Eventinvestor
Eventinvestor Feb. 6 at 7:13 PM
$SMX from $8–20 $BGMS from 1.20 to 🤩🤩🤩🤩🏦🏦🏦🏦🏦🏦🏦🏦🏦
0 · Reply
fromtheothersid3
fromtheothersid3 Feb. 6 at 7:09 PM
$BGMS got 4888 shares 1,20 ☺️
0 · Reply
Eventinvestor
Eventinvestor Feb. 6 at 7:07 PM
$LBTYB $BGMS
0 · Reply
Eventinvestor
Eventinvestor Feb. 6 at 7:03 PM
$BGMS 🫣🫣🫣🫣🫣🫣🫣🫣🫣🫣$FLYE $KTTA $SMX $YXT
0 · Reply